Nafiseh Abdolahi

Nafiseh Abdolahi

Auto-generated profile, based on publicly available information

Nafiseh Abdolahi

Golestan University of Medical Sciences

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2021 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
MMMaliheh Moradzadeh
Maliheh Moradzadeh
MAMehrdad Aghaei
Mehrdad Aghaei
ZMZahra Mehrbakhsh
Zahra Mehrbakhsh
ZAZahra Arab-Bafrani
Zahra Arab-Bafrani
NANafiseh Abdollahi
Nafiseh Abdollahi

31 July 2010 in Journal of Trace Elements in Medicine and Biology
Verified
Journal Article
Closed access
SSShahryar Semnani
Shahryar Semnani
GRGholamreza Roshandel
Gholamreza Roshandel
AZAzadehsadat Zendehbad
Azadehsadat Zendehbad
AKAbbasali Keshtkar
Abbasali Keshtkar
HRHadi Rahimzadeh
Hadi Rahimzadeh
SHSeyedzinab Hasheminasab
Seyedzinab Hasheminasab

21 July 2020 in Journal of Inorganic and Organometallic Polymers and Materials
Verified
Journal Article
Closed access
PDF file
MHMir Saleh Hoseininezhad-Namin
Mir Saleh Hoseininezhad-Namin
PPParinaz Pargolghasemi
Parinaz Pargolghasemi
MSMaryam Saadi
Maryam Saadi
MTMohammad Ramezani Taghartapeh
Mohammad Ramezani Taghartapeh
NANafiseh Abdolahi
Nafiseh Abdolahi
ALAndrew Ng Kay Lup
Andrew Ng Kay Lup

19 June 2020 in Trials
Verified
Journal Article
Open access
PDF file
NANafiseh Abdolahi
Nafiseh Abdolahi
EKEffat Kaheh
Effat Kaheh
RGRoghieh Golsha
Roghieh Golsha
BKBehnaz Khodabakhshi
Behnaz Khodabakhshi
ANAlireza Norouzi
Alireza Norouzi
GRGholamreza Roshandel
Gholamreza Roshandel
Objectives: There is little information about Coronavirus Disease 2019 (COVID-19) management for critically ill patients. Most of these patients develop acute respiratory distress syndrome (ARDS) due to excessive inflammatory response and the ensuing cytokine storm. Anti-inflammatory drugs including corticosteroids can be used to effectively reduce the effect of this cytokine storm and lung damage. However, corticosteroids can have side effects, so simultaneous administration of immunoglobulin (IV-IG) and interferon-beta can help manage treatment using corticosteroids. Therefore, we designed a trial to test our hypothesis that early administration of dexamethasone in combination with IV-IG and interferon-beta can reduce the effect of the cytokine storm in critically ill patients COVID-19. Trial design: A phase two multi-center randomized controlled trial (RCT) with three parallel arms (1:1:1 ratio). Participants: They will be hospitalized patients with severe COVID-19 who have positive RT-PCR test and have blood oxygen saturation levels (SpO2) less than 90% and respiratory rate higher than 24 per minute or have involvement of more than 50% of their lung when viewed using computed tomography (CT)-scan. The age range of patients will be 18-70 years old. Exclusion criteria: the need for intubation; allergy, intolerance, or contraindication to any study drug including dexamethasone, IV-IG, and interferon-beta; pregnancy or lactation; known HIV positive or active hepatitis B or C. The study will be conducted in several hospitals of the Golestan province, Iran. Intervention and comparator: The study subjects will be randomly allocated to three treatment arms: two experimental groups (two arms: Intervention 1 and Intervention 2) and one Control Group, which will be matched for age and sex using frequency matching method. Each eligible patient in the control arm will receive the standard treatment for COVID-19 based on WHO guidelines and the Ministry of the Health and Medical Education (MOHME) of Iran. Each patient in the Intervention Group 1 will receive the standard treatment for COVID-19 and dexamethasone, at the first 24 hours’ time of admission. The intervention begins with the administration of dexamethasone based on the SpO2 levels. If the level of SpO2 does not improve after 24 hours, IV-IG (400 mg/kg once daily for 5 days) and interferon-beta (7 doses every other day) will be prescribed along with dexamethasone administration. In Intervention Group 2, the administration of dexamethasone will be started within the first 24 hours’ time of admission and will be continued for 48-72 hours and then the SpO2 level will be checked. Then, if the level of SpO2 has not improved after that time, IV-IG and interferon-beta will be prescribed as the same dosage as Group 1. If the percentages of the SpO2 level are between 85 and 90/ 80 and 85/ 75 and 80/ less than 75, the dosages will be 4 mg every 12 hours/ 4 mg every 8 hours/ 8 mg every 12 hours/ 8 mg every 8 hours, respectively. According to the WHO recommendation, all participants will have the best available supportive care with full monitoring. Main outcomes: Primary: An increase in the SpO2 level to reach more than 90% in each case, which will be assessed by the oximeter. Secondary: The duration of hospital stays; intubation status and the percentage of patients who are free of mechanical ventilation; the mortality rates during hospitalization and one month after the admission time. Randomisation: Participants will be allocated into either control or intervention groups with a 1:1:1 allocation ratio using a computer random number generator to generate a table of random numbers for simple randomization. Blinding (masking): The project's principal investigator (PI) is unblinded. However, the PI will not analyse the data and interpret the results. An unblinded researcher (a pharmacist) will cover the drug’s bottles with aluminium foil and prepare them interventions and control drugs in a syringe with a code so that patients are blinded. This person will have no patients contact. The staff and nurses, caring for the patients, will be unblinded for each study group due to the nature of this study. The staff that take outcome measurements will be blinded. The laboratory technicians will also be blinded as well as the statistical team. These study statisticians will have access to coded data and will analyse the data labelled as group X, group Y, and group Z. Numbers to be randomised (sample size): The target sample size will be 105 critically ill COVID-19 patients, who will be allocated randomly to the three trial arms with 35 patients in each group. Trial status: Recruitment is ongoing. The study began on April 18 2020 and will be completed June 19 2020. This summary describes protocol version 1; April 2 2020. Trial registration: https://www.irct.ir/. Identifier: IRCT20120225009124N4 version 1; Registration date: April 2 2020. Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting the dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. The full protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines.

1 May 2007 in Pakistan Journal of Biological Sciences
Verified
Journal Article
Closed access
GRGholamreza Roshandel
Gholamreza Roshandel
SSShahryar Semnani
Shahryar Semnani
NANafiseh Abdolahi
Nafiseh Abdolahi
AKAbbas-Ali Keshtkar
Abbas-Ali Keshtkar
SBSima BESHARAT
Sima BESHARAT
SHSeyed Mohammad Hedayat-Mo
Seyed Mohammad Hedayat-Mo
This study was carried out to determine the seroprevalence of hepatitis D virus among HBsAg positive individuals in the northeast part of Iran. One hundred thirty nine HBsAg positive subjects detected from a population based single stage cluster sampling in Golestan province of Iran were enrolled. All cases were evaluated for the presence of anti-HDV antibodies using commercially available ELISA kits. Logistic regression was used to determine the relationship between independent variables and HDV seropositivity. Of 139 cases, 68 (48.9%) were males and 71 (51.1%) were females. The mean age was 41.89 +/- 11.30 years (25-64 years). Anti-HDV antibody was positive in 8 (5.8%) subjects with female predominance (9.9% versus 1.5%, p = 0.06; odds ratio = 7.32, 95% CI: 0.87-61.23). No significant relationship was seen between anti-HDV seropositivity and demographic factors such as age, place of residence and marital status. These findings showed that HDV infection was endemic in Golestan province (northeast) of Iran. Seroprevalence of Anti-HDV in the present study was higher than some previous studies from other parts of Iran. Our results suggest that the prevalence of HBV/HDV co-infection in Iran has increased during the last decade. Therefore, practitioners and all health care managers should be made aware of the risk of dual infection with HBV and HDV.

31 July 2019 in Current Rheumatology Reviews
Verified
Journal Article
Closed access
PDF file
MSMassoud Saghafi
Massoud Saghafi
NANafiseh Abdolahi
Nafiseh Abdolahi
ROReza Orang
Reza Orang
MHMohammad Reza Hatef
Mohammad Reza Hatef
MMMohammad Hadi Molseghi
Mohammad Hadi Molseghi
Background and Aim: Lymphoid cell infiltration and destruction of exocrine glands, specifically lacrimal and salivary glands are characteristics of Sjogren’s syndrome (SS). An etiological role has been proposed for Helicobacter pylori (H.Pylori), interacting in the clinical course and complications of SS (including gastric cancer and lymphoma). The aim of this study was to identify the probable correlation between H. pylori infection and Sjogren’s syndrome (SS). Method: In this case-control study, ELISA method was used to determine serum level of IgA and IgM anti H. pylori antibody in 43 subjects with SS according to the international criteria and 95 healthy subjects as control. SPSS-17 was used to analysis data with t-test. P value <0.05 were considered significant. Results: Serum level of IgM (34.9% vs 10.5%, p-value= 0.001) and IgA (67.4% vs 46.3% p value= 0.021) anti H.Pylori antibody were significantly higher in SS patients compared to the control group. There was a positive correlation between age and H.Pylori infection (r=0.2, P-value=0.05). Conclusions: Patients with SS had a higher prevalence of H. pylori infection compared to the normal population. Eradication of H.Pylori is recommended particularly in older patients with SS.